WO2006051172A1 - Method for testing a compound for a therapeutic effect and a diagnostic method - Google Patents
Method for testing a compound for a therapeutic effect and a diagnostic method Download PDFInfo
- Publication number
- WO2006051172A1 WO2006051172A1 PCT/FI2005/050417 FI2005050417W WO2006051172A1 WO 2006051172 A1 WO2006051172 A1 WO 2006051172A1 FI 2005050417 W FI2005050417 W FI 2005050417W WO 2006051172 A1 WO2006051172 A1 WO 2006051172A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pap
- gene
- prostatic
- compound
- disorder
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 48
- 150000001875 compounds Chemical class 0.000 title claims abstract description 30
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 12
- 238000012360 testing method Methods 0.000 title claims abstract description 8
- 238000002405 diagnostic procedure Methods 0.000 title claims abstract description 6
- 108010043671 prostatic acid phosphatase Proteins 0.000 claims abstract description 167
- 102100035703 Prostatic acid phosphatase Human genes 0.000 claims abstract description 153
- 230000000694 effects Effects 0.000 claims abstract description 55
- 230000007423 decrease Effects 0.000 claims abstract description 18
- 241000282414 Homo sapiens Species 0.000 claims abstract description 17
- 150000003907 phosphatidylinositol monophosphates Chemical class 0.000 claims abstract description 17
- 230000019491 signal transduction Effects 0.000 claims abstract description 16
- 238000001415 gene therapy Methods 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 49
- SZPQTEWIRPXBTC-KFOWTEFUSA-N 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'D-myo-inositol-3'-phosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H]1O SZPQTEWIRPXBTC-KFOWTEFUSA-N 0.000 claims description 44
- 208000035475 disorder Diseases 0.000 claims description 40
- 150000003915 phosphatidylinositol 4,5-bisphosphates Chemical class 0.000 claims description 35
- 241001465754 Metazoa Species 0.000 claims description 34
- 230000014509 gene expression Effects 0.000 claims description 26
- 230000001965 increasing effect Effects 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 12
- 150000003911 phosphatidylinositol 4-phosphates Chemical class 0.000 claims description 12
- 201000001119 neuropathy Diseases 0.000 claims description 9
- 230000007823 neuropathy Effects 0.000 claims description 9
- 230000004044 response Effects 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 9
- 208000021642 Muscular disease Diseases 0.000 claims description 8
- 201000009623 Myopathy Diseases 0.000 claims description 8
- 238000009825 accumulation Methods 0.000 claims description 8
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 230000033228 biological regulation Effects 0.000 claims description 6
- 230000009826 neoplastic cell growth Effects 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010020718 hyperplasia Diseases 0.000 claims description 4
- 241000701447 unidentified baculovirus Species 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 206010042135 Stomatitis necrotising Diseases 0.000 claims 1
- 201000008585 noma Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 58
- 210000002307 prostate Anatomy 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 29
- 101150073131 PAP gene Proteins 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 206010060862 Prostate cancer Diseases 0.000 description 24
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 18
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 18
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 17
- 230000006870 function Effects 0.000 description 14
- 239000012528 membrane Substances 0.000 description 14
- 101001001272 Homo sapiens Prostatic acid phosphatase Proteins 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 11
- 230000008685 targeting Effects 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- ZSZXYWFCIKKZBT-ZVDPZPSOSA-N [(2r)-3-[[(2s,3s,5r,6s)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O ZSZXYWFCIKKZBT-ZVDPZPSOSA-N 0.000 description 9
- 210000000170 cell membrane Anatomy 0.000 description 9
- 230000002950 deficient Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 210000001163 endosome Anatomy 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 230000011664 signaling Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 108010051457 Acid Phosphatase Proteins 0.000 description 8
- 102000030782 GTP binding Human genes 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 7
- 102000013563 Acid Phosphatase Human genes 0.000 description 7
- 108091006027 G proteins Proteins 0.000 description 7
- 108091000058 GTP-Binding Proteins 0.000 description 7
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical class O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 101150018624 ARF6 gene Proteins 0.000 description 6
- 101100379471 Drosophila melanogaster Arf51F gene Proteins 0.000 description 6
- 102000029749 Microtubule Human genes 0.000 description 6
- 108091022875 Microtubule Proteins 0.000 description 6
- 101001035658 Mus musculus 28 kDa heat- and acid-stable phosphoprotein Proteins 0.000 description 6
- 101000785917 Mus musculus Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 Proteins 0.000 description 6
- 101000735426 Mus musculus Poly(A) RNA polymerase, mitochondrial Proteins 0.000 description 6
- UBXIJOJXUFYNRG-RJKBCLGNSA-N PIP[3'](17:0/20:4(5Z,8Z,11Z,14Z)) Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(O)(O)=O)C1O UBXIJOJXUFYNRG-RJKBCLGNSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 206010071019 Prostatic dysplasia Diseases 0.000 description 6
- 230000035508 accumulation Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 230000008172 membrane trafficking Effects 0.000 description 6
- 210000004688 microtubule Anatomy 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 150000003912 phosphatidylinositol 5-phosphates Chemical class 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 102000030938 small GTPase Human genes 0.000 description 6
- 230000028973 vesicle-mediated transport Effects 0.000 description 6
- 108010011619 6-Phytase Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 101001035654 Homo sapiens 28 kDa heat- and acid-stable phosphoprotein Proteins 0.000 description 5
- 101000785915 Homo sapiens Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 Proteins 0.000 description 5
- 101000735427 Homo sapiens Poly(A) RNA polymerase, mitochondrial Proteins 0.000 description 5
- 102000043136 MAP kinase family Human genes 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 description 5
- 108091008611 Protein Kinase B Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 5
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 5
- 208000009956 adenocarcinoma Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 210000004292 cytoskeleton Anatomy 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000011813 knockout mouse model Methods 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000004064 recycling Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- HKWJHKSHEWVOSS-OMDJCSNQSA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O HKWJHKSHEWVOSS-OMDJCSNQSA-N 0.000 description 4
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 102000009193 Caveolin Human genes 0.000 description 4
- 108050000084 Caveolin Proteins 0.000 description 4
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 102000006386 Myelin Proteins Human genes 0.000 description 4
- 108010083674 Myelin Proteins Proteins 0.000 description 4
- 102100033817 Myotubularin Human genes 0.000 description 4
- 241001045988 Neogene Species 0.000 description 4
- 108091007960 PI3Ks Proteins 0.000 description 4
- 102000038030 PI3Ks Human genes 0.000 description 4
- 102000011420 Phospholipase D Human genes 0.000 description 4
- 108090000553 Phospholipase D Proteins 0.000 description 4
- 108090000315 Protein Kinase C Proteins 0.000 description 4
- UZMPYXSDDZXMAI-OHKKONBVSA-N [(2r)-2-hexadecanoyloxy-3-[hydroxy-[(2r,3r,5s,6r)-2,4,6-trihydroxy-3,5-diphosphonooxycyclohexyl]oxyphosphoryl]oxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OC1[C@H](O)[C@@H](OP(O)(O)=O)C(O)[C@@H](OP(O)(O)=O)[C@H]1O UZMPYXSDDZXMAI-OHKKONBVSA-N 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000003712 lysosome Anatomy 0.000 description 4
- 230000001868 lysosomic effect Effects 0.000 description 4
- 108091006026 monomeric small GTPases Proteins 0.000 description 4
- 210000005012 myelin Anatomy 0.000 description 4
- 101150091879 neo gene Proteins 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- -1 phosphatidylinositol 4-phosphate PI(4)P Chemical class 0.000 description 4
- 150000003905 phosphatidylinositols Chemical class 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 229940085127 phytase Drugs 0.000 description 4
- 102000016914 ras Proteins Human genes 0.000 description 4
- 108010014186 ras Proteins Proteins 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
- 102100035699 Lysosomal acid phosphatase Human genes 0.000 description 3
- 101710204480 Lysosomal acid phosphatase Proteins 0.000 description 3
- 208000010428 Muscle Weakness Diseases 0.000 description 3
- 206010028372 Muscular weakness Diseases 0.000 description 3
- 108090000697 Myotubularin Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 3
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 101001035657 Rattus norvegicus 28 kDa heat- and acid-stable phosphoprotein Proteins 0.000 description 3
- 102000014384 Type C Phospholipases Human genes 0.000 description 3
- 108010079194 Type C Phospholipases Proteins 0.000 description 3
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000001994 activation Methods 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 102000035181 adaptor proteins Human genes 0.000 description 3
- 108091005764 adaptor proteins Proteins 0.000 description 3
- 230000008848 allosteric regulation Effects 0.000 description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000003210 demyelinating effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 208000037765 diseases and disorders Diseases 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000002132 lysosomal effect Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 230000000865 phosphorylative effect Effects 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 210000005267 prostate cell Anatomy 0.000 description 3
- 210000003079 salivary gland Anatomy 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 108060007624 small GTPase Proteins 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 230000007730 Akt signaling Effects 0.000 description 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101100292480 Caenorhabditis elegans mtm-1 gene Proteins 0.000 description 2
- 102000011068 Cdc42 Human genes 0.000 description 2
- 108050001278 Cdc42 Proteins 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 102000005915 GABA Receptors Human genes 0.000 description 2
- 108010005551 GABA Receptors Proteins 0.000 description 2
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102100040602 Myotubularin-related protein 2 Human genes 0.000 description 2
- 101710105136 Phosphatidylglycerophosphatase and protein-tyrosine phosphatase 1 Proteins 0.000 description 2
- 102100037408 Phosphatidylglycerophosphatase and protein-tyrosine phosphatase 1 Human genes 0.000 description 2
- 101710132081 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 2
- 102100032421 Protein S100-A6 Human genes 0.000 description 2
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 2
- 101001001270 Rattus norvegicus Prostatic acid phosphatase Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 101150077759 Ywhae gene Proteins 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000002121 endocytic effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000028023 exocytosis Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 238000011819 knockout animal model Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000002370 liquid polymer infiltration Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 2
- 229940107698 malachite green Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000003007 myelin sheath Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- FDIKHVQUPVCJFA-UHFFFAOYSA-N phosphohistidine Chemical compound OP(=O)(O)NC(C(=O)O)CC1=CN=CN1 FDIKHVQUPVCJFA-UHFFFAOYSA-N 0.000 description 2
- 150000003906 phosphoinositides Chemical class 0.000 description 2
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 2
- 210000004116 schwann cell Anatomy 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
- 108700020469 14-3-3 Proteins 0.000 description 1
- 102000004899 14-3-3 Proteins Human genes 0.000 description 1
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 101150113498 Atp2c1 gene Proteins 0.000 description 1
- 108010029692 Bisphosphoglycerate mutase Proteins 0.000 description 1
- 241001504766 Bovichtus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 101150104494 CAV1 gene Proteins 0.000 description 1
- 101100024648 Caenorhabditis elegans mtm-6 gene Proteins 0.000 description 1
- 101710200183 Calcium/calmodulin-dependent protein kinase I Proteins 0.000 description 1
- 102100033086 Calcium/calmodulin-dependent protein kinase type 1 Human genes 0.000 description 1
- 108091007958 Class I PI3Ks Proteins 0.000 description 1
- 108091007963 Class III PI3Ks Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 101150045737 DUSP4 gene Proteins 0.000 description 1
- 101150105088 Dele1 gene Proteins 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Diphosphoinositol tetrakisphosphate Chemical compound OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
- 101710132801 Dual specificity protein phosphatase 4 Proteins 0.000 description 1
- 102100027085 Dual specificity protein phosphatase 4 Human genes 0.000 description 1
- 101000688187 Escherichia coli (strain K12) Phytase AppA Proteins 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 1
- 102000027487 Fructose-Bisphosphatase Human genes 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 101710179023 Glucose-1-phosphatase Proteins 0.000 description 1
- 102100021223 Glucosidase 2 subunit beta Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 1
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101000684275 Homo sapiens ADP-ribosylation factor 3 Proteins 0.000 description 1
- 101001040875 Homo sapiens Glucosidase 2 subunit beta Proteins 0.000 description 1
- 101000730665 Homo sapiens Phospholipase D1 Proteins 0.000 description 1
- 101000869703 Homo sapiens Protein S100-A6 Proteins 0.000 description 1
- 101001130437 Homo sapiens Ras-related protein Rap-2b Proteins 0.000 description 1
- 101001077660 Homo sapiens Serine protease inhibitor Kazal-type 1 Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 101000964266 Loxosceles laeta Dermonecrotic toxin Proteins 0.000 description 1
- 101150018665 MAPK3 gene Proteins 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 241000332699 Moneses Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100225689 Mus musculus Enah gene Proteins 0.000 description 1
- 101001001271 Mus musculus Prostatic acid phosphatase Proteins 0.000 description 1
- 101100156953 Mus musculus Rp2 gene Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 101710147282 Myotubularin-related protein 2 Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101150046749 PI4KB gene Proteins 0.000 description 1
- 101150095793 PICALM gene Proteins 0.000 description 1
- 101150046396 PIK3R1 gene Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 101150101473 Pfn1 gene Proteins 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 102000011025 Phosphoglycerate Mutase Human genes 0.000 description 1
- 101150008336 Pik3r4 gene Proteins 0.000 description 1
- 101150107582 Plpp1 gene Proteins 0.000 description 1
- 101150109527 Plpp3 gene Proteins 0.000 description 1
- 108010080283 Pre-beta High-Density Lipoproteins Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 101150060955 RAB11A gene Proteins 0.000 description 1
- 101150008969 RAB14 gene Proteins 0.000 description 1
- 101150066312 RAB2A gene Proteins 0.000 description 1
- 101150030875 RAB7A gene Proteins 0.000 description 1
- 101150058540 RAC1 gene Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 1
- 102100022873 Ras-related protein Rab-11A Human genes 0.000 description 1
- 101150067744 Rgs2 gene Proteins 0.000 description 1
- 101150054980 Rhob gene Proteins 0.000 description 1
- 101150006306 Rhoq gene Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010005260 S100 Calcium Binding Protein A6 Proteins 0.000 description 1
- 101150008262 STK24 gene Proteins 0.000 description 1
- 102100025144 Serine protease inhibitor Kazal-type 1 Human genes 0.000 description 1
- 102100026764 Serine/threonine-protein kinase 24 Human genes 0.000 description 1
- 101710183946 Serine/threonine-protein kinase 24 Proteins 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 101150048952 TPM-1 gene Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 108091000387 actin binding proteins Proteins 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 206010003882 axonal neuropathy Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004323 caveolae Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000002806 clathrin-coated vesicle Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001278 effect on cholesterol Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 101150098203 grb2 gene Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000000260 male genitalia Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 125000002320 montanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000002487 multivesicular body Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940072417 peroxidase Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 108010085734 phosphofructokinase phosphatase Proteins 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000000064 prostate epithelial cell Anatomy 0.000 description 1
- 108010080187 protein AG-gold complex Proteins 0.000 description 1
- 101150057187 rab-18 gene Proteins 0.000 description 1
- 101150093614 rab4a gene Proteins 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 102000005912 ran GTP Binding Protein Human genes 0.000 description 1
- 108010005597 ran GTP Binding Protein Proteins 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
- 230000035938 sexual maturation Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000003518 stress fiber Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004654 survival pathway Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 108010016910 synaptojanin Proteins 0.000 description 1
- 102000000580 synaptojanin Human genes 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/507—Pancreatic cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/16—Phosphorus containing
- Y10T436/163333—Organic [e.g., chemical warfare agents, insecticides, etc.]
Definitions
- the present invention relates to methods for testing and screening for a compound for a therapeutic effect for treating disorders related to unbalanced phosphatidy- linositol phosphate cascade and/or signaling pathway. More particularly the pre ⁇ sent invention relates to methods utilizing a prostatic acid phosphatase knockout non-human animal model. The present invention also relates to diagnostic meth ⁇ ods and methods for treating disorders related to phosphatidylinositol phosphate cascade and signaling pathway.
- Mammalian prostatic and lysosomal acid phosphatases include a co- valent phosphohistidine intermediate in their reaction mechanism, and they are thus called histidine acid phosphatases.
- the same histidine acid phosphatase group includes E. coli pH 2.5 acid phosphatase and glucose-1 -phosphatase, yeast acid phosphatases, Aspergillus phytases A and B, and E. coli phytase.
- coli phy- tase catalyzes the sequential hydrolysis of phosphate phytate (myo-inositol- 1 , 2,3,4, 5,6-hexa/f/sphosphate, IP 6 ) to less phosphorylated myoinositol derivatives and inorganic phosphate. and its derivatives have functions in RNA export, DNA repair, and DNA recombination and in endocytosis and vesicular trafficking.
- the inventor's earlier structural studies of PAP showed that the ⁇ / ⁇ domain re ⁇ ttles the structure of phosphoglycerate mutase. This domain contains a se ⁇ quence motif that is also present in the bifunctional phosphofructokinase/fructose bisphosphatase.
- the active site of PAP is a rather open, readily accessible cleft. Despite low sequence homology (14% identity), the crystal structure of E. coli phy ⁇ tase is closely related to PAP.
- the histidine residue in the conserved motif, RHGXRXP serves as a nucleophile in the formation of a covalent phosphohis ⁇ tidine intermediate, and the aspartatic acid residue of the C-terminal conserved histidine domain motif serves as a proton donor to the oxygen atom of the phos- phoester bond.
- hPAP has been unclear. It has been suggested that the growth- suppressing effect of hPAP is due to its intrinsic protein tyrosine phosphatase ac ⁇ tivity, and this suggestion was supported by theoretical modelling and molecular- dynamic simulation methods, which demonstrated that EGFR and its homologue ErbB-2 could be possible in vivo ligands. The theory is further supported by the declining phosphorylation status of ErbB-2 after intratumoral administration of hPAP cDNA. However, hPAP has also been shown to be a universal protein phosphatase that hydrolyzes equally well the phosphotyrosine, -serine, and -threonine residues.
- the activity of hPAP is lower in prostate carcinomas than in normal prostates, and both hPAP mRNA and protein levels are decreased or absent in prostate carcinoma tissue. Similar effects can be observed in prostate cancer cell lines: the hPAP-expressing LNCaP cell line has a slower proliferation rate than the non-expressing PC-3 and DIM 45 cells. Studies with transfected hPAP support the growth-suppressing effect.
- the present inventor has earlier demonstrated the binding of hPAP to the main high-density lipoprotein apolipoprotein A-1 (apoA-1 ). ApoA-1 is lipidated during its progress through intracellular vesicle traffic from the cell surface lipid raft into early endosomes, late endosomes, and finally back to the cell surface as a nascent HDL particle.
- apoA-1 main high-density lipoprotein apolipoprotein A-1
- Animal models such as transgenic or knockout animal models, may be used to investigate disorders related to certain genes.
- One such disorder is prostate cancer or tumor, which has been shown in the current invention to be associated with prostatic acid phosphatase in a specific way.
- prostatic acid phosphatase in a specific way.
- animal models which promote the formation of prostate tumor.
- Genetically defined mouse models that mimic natural aspects of human prostate cancer development discloses several known mouse models for prostate cancer and exploitation thereof. This and all the other publications and other material disclosed herein are incorporated by reference.
- the PTEN phosphatase and tensin homolog deleted on chromosome 10 tumor suppressor gene is one of the most frequently mutated/deleted genes in various human cancers.
- Wang et al. (Cancer Cell 4, 209-221) disclose a murine PTEN prostate cancer model.
- WO 2004096153 describes prostate cancer therapeutics and speculates on ani ⁇ mal models having knockout prostatic acid phosphatase gene.
- no actual animal models were disclosed.
- the present invention is based on the finding that decrease or absence of the ac ⁇ tivity of prostatic acid phosphatase (PAP) is related to certain disorders not asso ⁇ ciated to PAP before. These diseases and disorders relate to unbalanced phos- phatidylinositol 3-phosphate (PI(3)P) and PI(4,5)P 2 signaling pathway.
- PAP prostatic acid phosphatase
- One aspect of the present invention relates to a method for testing and screening for compound for an therapeutic effect, said method comprising the steps of ad ⁇ ministering said compound to a cell or a non-human animal having disruption in the prostatic acid phosphatase gene or regulation thereof resulting in a decrease or absence of the activity or the level of prostatic acid phosphatase, and determin ⁇ ing if said compound substantially restores the unbalanced phosphatidylinositol phosphate signaling pathway related to PAP expression or activity on said cell or said animal, said restoring indicating said compound being therapeutically effec- tive for treating disorders related to unbalanced phosphatidylinositol phosphate signaling pathway.
- the response of said restoring may be decrease in PI(4,5)P2 accumulation or decrease in the level of PI(3)P, caused by the recovered PAP ac ⁇ tivity or level of expression.
- substantially restoring refers to such restoration or normalization of unbalanced PIP signaling pathway, either complete or partial, which has therapeutic value and effect.
- Another aspect of the present invention relates to diagnostic method wherein the increased level of PI(4,5)P2 is used to indicate the presence of a disease or disor ⁇ der related to unbalanced phosphatidylinositol phosphate signaling pathway.
- One aspect of the present invention relates to therapeutic compounds obtained by said screening method.
- Another aspect of the current invention relates to methods for treating disorders related to unbalanced phosphatidylinositol phosphate cascade and/or signaling pathway related to prostatic acid phosphatase resulting in PI(4,5)P2 accumulation, increased level of PI(3)P or increased ratio of PI(4,5)P2/PI(4)P, by administering a patient suffering said disorder compound which increases the level of expression or activity of PAP or by giving said patient gene therapy which increases the level or restores the activity of PAP.
- the present invention utilizes a knockout animal model wherein the prostatic acid phosphatase gene in the genome of said animal has been disrupted resulting in a decrease in the activity or the level of prostatic acid phosphatase.
- Said knockout animal expresses a reduced level or activity of PAP enzyme in certain cells or tis ⁇ sues or preferably does not express PAP at all.
- an isolated knockout animal or plant cell such as a prostate cell
- Such cells may be cultured and used to investigate disorders related to PAP and its function.
- the animals described above may be used as a source of said cells.
- said cell may be a human cell line, such as one derived from a human cancer cell line.
- PAP which is a tyrosine phosphatase
- AP anterior
- DLP dorsolateral
- PAP activity for example inflicts changes in the prostate in every animal in the anterior (AP) and dorsolateral (DLP) lobes. These animals are viable and fertile and they develop benign prostate hy ⁇ perplasia followed by initiation of prostate cancer with prostate intraepithelial neo- plasia (PIN) and invasive adenocarcinoma.
- PIN prostate intraepithelial neo- plasia
- PI(3)P invasive adenocarcinoma.
- the results also show that PAP is not only an important regulator of PI(3)P transport, but also a novel tumor suppressor of prostate epithelial cells.
- PAP dephosphorylates phosphatidylinositol 3-phosphate, which is a phospholipid. Inactivation of PAP leads to inbalance of phosphoinositide (phosphatidylinositol phosphate) cascade and to increase of PI(3)P and even more remarkable in ⁇ crease of PI(4,5)P2. This leads to changes in membrane and vesicular traffic and cytoskeleton of the cell. In addition G-protein and small GTPase signaling is changed. In addition PAP is connected to cholesterol transport and it has choles ⁇ terol binding domains. Unbalaced Pl-cascade is also dependent on cell lipid me ⁇ tabolism. Diseases like prostate, bladder and pancreatic cancer, myopathy (myo- degeneration) and neuropathy (neurodegeneration) may be caused by said inbal- anced Pl-cascade.
- the knockout animal or cell model may be utilized in several ways. It may be used when investigating prostatic intraephitelial neoplasia or other disorders related to prostatic acid phosphatase and function thereof. It may also be used when devel ⁇ oping and screening drugs for treating such diseases. Also the roles of certain hor ⁇ mones related to said disorders may be investigated.
- the animal or cell model of the present invention is directed not only to prostate cells but any other cell or tissue types naturally expressing PAP. The same disease mechanism may lead to cancer or other disorders of said other cells or tissues, such as salivary gland, kid ⁇ ney, lung, granulocytes, Langerhans cells, muscle, Schwann cells or other cells and tissues.
- the knocking out of naturally existing enzyme such as PAP
- PAP will provide a useful model for investigating disorders related to said enzyme.
- the model used in the present invention utilizes a simple approach of switching off a naturally existing PAP enzyme activity (e.g. in the prostate) as such decrease in said activity is now known to be related to certain disorders, such as prostatic intraepithelial neoplasia (PIN) and carcinoma.
- PIN prostatic intraepithelial neoplasia
- FIG 1 shows the generation of PAP* 3 ** 3 deficient mouse:
- Figure 2 shows the PAP found on (A) plasma membrane, (B) membrane- associated vesicles in mouse prostate, (C) caveosome-like vesicles, (D) early en- dosome-line vesicles and (E) lysosomes.
- Figure 3 shows the increased number of enlarged vesicles and increased api- cal and basolateral exocytosis-like secretion (A-D).
- Figure 4 shows gradual development of atypical changes (A-H).
- FIG 5 shows how muscle weakness was detected in PAF 1' mice (A-D), impaired myelin formation (F-H), electrophysiological measurements of sensory and motor conduction on tail nerve (I 1 J) and disorganized fibers, inclusions and enlarged vesicles (L 1 M).
- Figure 6 shows changes in the gene expressions of Pl-kinases, their adaptor proteins and Pl-phosphatases (A) and Western blot results showing an increased amount of PTEN phosphorylated (B).
- Figure 7 shows the generation of PAP activity-deficient mouse.
- the PAP gene product is expressed in every prostate lobe. Splicing out of exon 3 results in a gene product of 557 nt in PAP 1' mice.
- Figure 9 shows smooth muscle ⁇ -actin staining of the fibromuscular sheath.
- a 1 D Normal fibromuscular sheath structures in the DLP and AP lobes of PAP +/+ mice.
- B The fibromuscular sheath is thin and irregular and tends to break down in the DLP of a PAF 1' mouse.
- C Adenocarcinoma shows different stages of dif ⁇ ferentiation.
- E 1 F The fibromuscular sheath is losing its structure in the AP of a PAF 1' mouse. Epithelial cells are bulging against the fibromuscular sheath (white arrow), and cancerous cells are breaking through (black arrows). Epithelial cells are visible in a blood vessel (*). An inflammatory response can be detected.
- ML multilayer epithelium
- SL single-layer epithelium
- knockout refers to a process of purposely removing a particular gene or trait from an organism or cell.
- a knockout is a site-specific integration that usually deletes an essential part of a gene of interest.
- Methods of making knockouts are generally known in the art, for example microinjection and targeted mutation methods.
- the knockouts of the present invention may be done with any known knockout methods, such as any heritable modifications of the PAP gene, as long as they result to substantial disruption of at least part of the PAP gene or an expression regulation region thereof resulting in substantial disruption of the original function of expressed PAP enzyme or the original function of PAP gene.
- the knockout is done by replacing a part of the PAP gene with an external nucleic acid molecule and introducing this modified gene into the genome of the animal to replace the original PAP gene.
- the knockout may also be done by removing the whole gene of interest.
- substantially disrupted or “substantially reduced” are herein intended to mean that substantially lower amount of normal PAP gene product is produced in cells or in organism when compared to normal cells or organisms. Preferably such lower amount refers to essentially undetectable amount of normal gene product.
- This type of mutation is generally called as a “null mutation” and an animal carrying such a mutation is also referred to as a “knockout animal”.
- knockout animal an animal carrying such a mutation
- the "decrease in activity" of the PAP as used herein refers to a decrease of total enzyme activity of said disrupted or substantially disrupted PAP gene product in certain cells. Said decrease in activity may be partial or the activity may be totally lost and it is sufficient to cause disorders related to PAP gene, such as described in the specification. Said decrease in activity may relate for example to reduced level of expressed PAP, for example if the promoter region of the PAP gene has been altered, or to disrupted structure or function of PAP enzyme. "Decrease in the activity of (expressed) PAP” refers not only to expressed PAP which has lower activity compared to normal PAP, but also to PAP which is expressed at lower lev ⁇ els than normally. This embraces also PAP which is substantially not expressed at all.
- the "PAP gene” as used herein refers to any suitable prostatic acid phosphatase gene or homologue or derivative thereof.
- the PAP gene to be used in the present invention may be of any suitable origin, plant or animal, such as rat, mouse or hu ⁇ man PAP gene.
- the human prostatic acid phosphatase (hPAP) gene is used to provide a model for investigating human PAP-related disorders.
- the human PAP gene may be inserted to another species, such as rat or mouse, or to a cell thereof, to provide a transgenic animal or cell model for investigating said disorders or diseases.
- PAP genes of other origins may be used, such as mouse PAP (mPAP) or rat PAP (rPAP).
- any PAP gene from any suit ⁇ able organism, which will produce, when expressed in a cell, a substantially func- tional PAP enzyme may be used.
- Such PAP gene may be a homologue of a known PAP gene from certain species having insertions or deletions of amino ac ⁇ ids, but still having sufficient homology with the original gene to produce substan- tially analogous PAP enzyme.
- Such homology is preferably at least 50%, more preferably 80% and most preferably 90% at amino acid level.
- Phosphatidylinositol phosphate refers to any phosphatidylinositol phos- phate as described herein, such as phosphatidylinositol 3-phosphate PI(3)P, phosphatidylinositol 4-phosphate PI(4)P, PI(5)P, Pl(3,5) 2 , PI(4,5)P 2 , PI(3,4,5)P 3 or corresponding soluble inositol phosphate (IP).
- PIP soluble inositol phosphate
- the inventor of the present invention simultaneously modeled, based on the conserved active site amino acid residues of PAP and E. coli phytase, inositol phosphates (IP) and phosphorylated phos- phatidylinositols, collectively called phosphoinositides (Pl), as substrates, studied the subcellular localization of PAP, and generated a PAP activity-deficient mouse model by deleting the 3rd exon of the PAP gene.
- IP inositol phosphates
- Pl phosphorylated phos- phatidylinositols
- PAP is a phosphatidylinositol 3-phosphate [PI(3)P] phosphatase on the endosomal path ⁇ way, and that knockout of PAP activity results in a changed Pl- kinase/phosphatase cascade favorable for PI(4,5)P2 accumulation, which is causa- tive of altered G-protein signaling and vesicular/membrane trafficking and of pros ⁇ tate adenocarcinoma, myopathy and neuropathy.
- PI(3)P phosphatidylinositol 3-phosphate
- the current invention utilizes knockout animals and cells wherein at least one al ⁇ lele of an endogenous prostatic acid phosphatase (PAP) gene is functionally dis- rupted in somatic and/or germ cells.
- Said animals or cells may be heterozygous or, preferably, homozygous for the PAP knockout.
- Animals to be used in the animal model of the present invention include any suit ⁇ able non-human animals, such as vertebrates, or more particularly mammals.
- the term animal includes an individual animal in all stages of development, including embryonic and fetal stages.
- the animal is a rodent, such as mouse or rat, which are generally used as similar applications may be adapted to both species.
- the cells to be used include any suitable cells, from plants or animals, for example ones derived from the animal described above or human cell lines.
- the disruption may be made to exon 3 of the PAP gene. This is preferred because exon 3 is involved with PAP activity. This will ensure that the activity of the PAP enzyme will be abolished. Said exon 3 may be knocked out totally or its function may be decreased partially. However, similar disruptions or knockouts may be also made to another suitable part of PAP gene, for example by introducing dele ⁇ tions or insertions of nucleic acids to obtain the defective PAP. The PAP gene may also be totally removed. Said disruption may also refer to the level of expressed gene product.
- Said disruption may be introduced into said prostatic acid phosphatase gene by replacing at least part of it with an external nucleic acid sequence.
- an external nucleic acid sequence is the commonly used neo cassette.
- Said prostatic acid phosphatase gene may be originated from different species, such as human, mouse or rat prostatic acid phosphatase gene or homologue thereof, or it is a recombinant PAP gene.
- Said external nucleic acid molecule used for replacing part of the PAP gene may be any suitable nucleic acid molecule containing suitable nucleic acid sequence which is able to decrease the activity or level of expressed prostatic acid phos ⁇ phatase when inserted to the PAP gene, for example at the location of exon 3.
- Targeting to generate a null or mutated allele is usually accomplished by insertion of a selectable marker into a gene causing disruption of splicing, promoter func ⁇ tion, or reading frame, with or without deletion of some of the gene.
- One com ⁇ monly used selectable marker gene for making knockouts is the neo gene, which confers resistance to the antibiotic neomycin. Also other suitable sequences may be used.
- One embodiment of the present invention provides methods of screening a com ⁇ pound, such as a drug candidate, for a therapeutic effect, comprising: a) exposing the knockout animal or cell to a compound and b) determining the response of the animal or cell to the compound.
- a change in response compared to the response of a knockout animal or cell not exposed to the com ⁇ pound indicates the response to the compound.
- Such control animal may be ex ⁇ posed for example to placebo or other compound.
- the re ⁇ sponse of a knockout animal or cell is compared to one of a wild type animal.
- the knockout animals or cells are examined directly without comparison to a wild-type animal. Such methods are generally well known in the art.
- Said therapeutic effect is against a disorder related to prostatic acid phos ⁇ phatase.
- disorders are prostatic atypical hyperpla ⁇ sia, prostatic intraephitelial neoplasia, carcinoma and other disorders related to phosphorylation/dephosphorylation or transport of phosphatidylinositol 3- phosphate (PI(3)P).
- PI(3)P phosphatidylinositol 3- phosphate
- said disorder may be associated with the PI(3)P metabolism and related mechanisms, such as insulin response, lipid metabolism, growth factor response, cell division, apoptosis etc., which are regulated by PI(3)P.
- Said diseases and disorders include prostate, bladder and pancreatic cancer, myopathy (myodegeneration) and neu ⁇ ropathy (neurodegeneration).
- a compound found with the method of the invention may be used as medicament for treating the disorders disclosed herein.
- Non- limiting example of such compound may be a compound acting as an enhancer for the expression of PAP.
- One embodiment of the present invention provides diagnostic methods wherein the increased level of PI(4,5)P2 measured from a sample is used to indicate the presence of a disease or disorder related to unbalanced phosphatidylinositol phosphate cascade or signaling pathway related to prostatic acid phosphatase as described herein.
- a person skilled in the art can easily select a method for meas ⁇ uring the level of PI(4,5)P2 and also compare the measured values to normal ref ⁇ erence values in order to make the diagnosis.
- the general level of PI(4,5)P2 de ⁇ fined from a healthy reference group may be used as reference when defining said increased level of PI(4,5)P2.
- Said sample may be in vitro or in vivo sample, such as one taken from a tissue suffering from suspected disorder or disease or the like.
- the increased ratio of PI(4,5)P2/PI(4)P is further used to indicate the presence of said diseases or disorders. Normally this ratio is about 1 , but in pathological conditions the level of PI(4,5)P2 is increased and the ratio is substantially over 1 , for example about 2, 3 or 4.
- One embodiment of the present invention provides methods for treating said dis ⁇ eases or disorders related to PAP by gene therapy and other methods to restore the activity of PAP.
- a compound affecting to the expression or effect of PAP may be administered to tissues or cells of a patient suffering a condition or disorder re ⁇ lated to PAP, as described above.
- gene therapy affecting to or restoring the activity of PAP may be given to such patient.
- the gene therapy preferably restores at least part of the PAP activity.
- Suitable genes to be used in such gene therapy include any suitable PAP gene or nucleotide vector of the invention as described herein.
- the gene therapy or other treatment may be administered to the patient for example by injection to target, such as to prostate or by prostate artery, as a virus vector.
- virus vectors which may be used to carry the PAP gene include baculo, adeno and lenti viruses (see e.g. Airenne et al.: “Baculovirus-mediated Gene Transfer: An Evolving New Concept", Templeton NS, ed. Gene and Cell Therapy, 181-197, New York, Marcel Dekker, 2004; Kost et al.: "Baculovirus as versatile vectors for protein expression in insect and mammalian cells, Nature Bio ⁇ technology 2005:23, 567-575).
- PAP knockout (KO) mouse model was generated by deleting the 3 rd exon of the mPAP gene.
- the pre- sent inventor found out that PAP is PI(3)P-lipid phosphatase, regulates PI(3)P membrane traffic, and its inactivation is causative for prostate cancer.
- the corre ⁇ sponding publication (Vihko PT, Quintero I, Ronka AE, Herrala A, Jantti P, Porvari K, Lindqvist Y, Kaija H, Pulkka, A, Vuoristo J, et al.
- PAcP Prostatic acid phos ⁇ phatase
- the PAP " ' " mouse is the model for invasive prostate cancer both in AP and DLP lobes. Gene expression and subcellular changes are detected long before histo ⁇ logical changes.
- PAP is a novel PI(3)P-phosphatase and allosterically regulated
- Phosphatidylinositol constitutes about 8% of all phospholipid in mammalian cells. It is present in the cytoplasmic leaflet of various cellular membranes. Activa- tion of cell membrane receptors by extracellular stimuli leads to generation of sec ⁇ ond messengers from phosphatidylinositol by specific kinases (PI3Ks) phosphory- lating the inositol headgroup of Pl in cells in the 3-, 4- or 5-position. Pl and its phosphorylated derivates recruit effector proteins to specific subcellular localiza- tions and contribute to their activity.
- PI3Ks specific kinases
- PI(3)P, PI(4)P, Pl(3,5) 2 and Pl(4,5) 2 have im ⁇ portant, albeit not completely elucidated roles both in regulated and constitutive membrane traffic.
- the differential intracellular distribution of PIPs can be achieved by localized synthesis and degradation resulting from restricted distribution of Pl- kinase and Pl-phosphatase isoforms. Many of these kinases and phosphatases are cytosolic enzymes, and their targeting to different intracellular domains is not completely elucidated. It is however known to often involve small GTPases and GTP-binding proteins.
- PI3Ks can be divided into three classes.
- class I and class Il PI3Ks utilize Pl, PI(4)P, and PI(4,5)P 2 as substrates, with the preference of class I PI3K for PI(4,5)P 2 and class Il PI3K for PIs.
- Class III PI3Ks only use PIs as a substrate in vitro, and are believed to be responsible for the generation of the majority of the PI(3)P in cells. Differing from the cytosolic localization of class I PI3Ks, class Il en- zymes are predominantly membrane-bound.
- PI3K-C2 ⁇ has a carboxyl terminal phospholipid and Ca 2+ binding domain C2 and it has been demonstrated in nuclear membranes and the nucleus.
- PAP is a novel PI(3)P-phosphatase.
- Pl-phosphatases can be divided into different groups based on their favored substrate: 3- and 4- phosphatases from the CX 5 R families and type Il 5-phosphatases.
- CX 5 R has been identified as an active site motif of the protein tyrosine phosphatase family. Only a few tyrosine phosphatases have been shown to possess inositol lipid phosphatase activity.
- the best-known PI(3)P-phosphatases so far are myotubularin (MTM) and phosphatase and tensin homolog deleted on chromosome 10 (PTEN).
- MTM myotubularin
- PTEN phosphatase and tensin homolog deleted on chromosome 10
- Allosteric regulation is characteristic of Pl-phosphatases.
- Kinetic analysis of PAP with PI(3)P showed that plots of initial reaction velocity as a function of substrate concentration are not hyperbolic, and hence PAP does not obey Michaelis-Menten kinetics, but sigmoidal curves were obtained. This suggests an allosteric regulation mechanism.
- PTEN and phosphatases of the myo ⁇ tubularin family have been reported to be regulated through allosteric mechanism by the end product or by other PIP.
- PTEN is hydrolyzing PI(3,4,5)P 3
- the end product, PI(4,5)P 2 regulates the phosphatase activity of PTEN in vitro through an allosteric mechanism.
- MTM 1 and MTM6 hydrolyze mostly PI(3)P and PI(3,5)P 2 in vitro, and PI(5)P has been reported to have a positive feedback effect on both reactions.
- PTEN and myotubularins which besides their favor ⁇ ite substrate, hydrolyze other PIP-compounds, although less effectively, PTEN-like phosphatase (PLIP) hydrolyzed specifically only PI(5)P, and the activity showed a hyperbolic dependence on substrate concentration.
- PLIP PTEN-like phosphatase
- ⁇ represents residue of F, W or Y, X represents any amino acid, and X(1-5) one to five residues of any amino acids.
- Mouse DLP is considered most similar to the human peripheral zone, where most detected cancers arise.
- Mouse AP is considered analogous to the human central zone around the urethra, where cancers exist and are detected by transurethral resection.
- Mouse VP has no human homolog and the human transitional zone has no mouse homologue.
- Mouse prostate cancer models have been created either via transgenic or knock ⁇ out approaches. So far, the transgenic adenocarcinoma mouse prostate (TRAMP) (Greenberg et al., 1995, Proc. Natl. Acad. Sci. U.S.A. 92, 3439-3443; Garabedian et al., 1998, Proc. Natl. Acad. Sci. U.S.A.
- TRAMP transgenic adenocarcinoma mouse prostate
- PAP is an important regulator of the function of the prostate gland and its inactivation is causative for prostate cancer.
- the PAF 1' mouse model of prostate can ⁇ cer will be beneficial for science and patients.
- mice mice
- suitable animals for example rats.
- the PAPs and the functions thereof described herein are similar among different spe ⁇ cies.
- PAP is PI(3)P-lipid phosphatase
- PAP binds strongly only to PI(3)P ( Figure 1 D). PAP showed no affinity to the other lipids tested: lysophosphatidic acid, lysophosphocholine, Pl, PI(4)P, PI(5)P, PI(3,4)P 2 , PI(3,5)P 2 , PI(4,5)P 2 , PI(3,4,5)P 3 , phosphatidylethanolamine, phosphatidylcholine, sphingosine-1 -phosphate, phosphatidic acid, or phosphati- dylserine. This shows that PI(3)P is a principal substrate for PAP.
- PAP is found on plasma membrane (Figure 2A) and is membrane-associated in vesicles in mouse prostate (Figure 2B). IEM studies with LNCaP cells showed PAP to be topological ⁇ present on the Pl pathway: caveosome-like vesicles (Fig ⁇ ure 2C), early endosome-like vesicles (Figure 2D), and lysosomes (Figure 2E). PAP-deficient mice develop adenocarcinoma of prostate, myopathy, and neuropathy
- PAP has so far also been found to be expressed in lactating mammary gland, sali- vary gland, Schwann cells, muscle, liver, lung, kidney, spleen, thymus, bladder, Langerhans islets (Figure 8) and granulocytes.
- prostate cells of two-month-old PAP-deficient mice had lost their microvilli and single-layer colum ⁇ nar epithelial structure, characteristic of the loss of cell polarity.
- the increased number of enlarged vesicles and increased apical and basolateral exocytosis-like secretion were seen with filament structures stacking inside the epithelial cells of PAF 1' prostates (Figure 3A-D).
- the PI(3)P, PI(3,4)P 2 , and PI(3,4,5)P 3 are all dephosphorylated by PTEN.
- Pten was upregulated (+2.1x).
- Extensive downregulation of the gene for Inpp ⁇ f (-26x) dephosphorylating PI(4,5)P 2 and PI(3,4,5)P 3 was detected.
- the gene for Pip5k3, which phosphorylates Pl to PI(4)P and further to PI(4,5)P 2 was upregulated (+2.5x).
- the expression of the PI4K-encoding gene, Pik4cb was however decreased (-4.Ox).
- PLC phospholipase C
- PLD is positively regulated by protein kinase C (PKC), Arf6, and Pl(4,5) 2 , which, in the case of PLD1 , also localizes the enzyme to the plasma membrane.
- PKC protein kinase C
- Arf6 was downregulated -7.Ox.
- the Ywhae gene for tyrosine-3 monooxygenase was down- regulated -9.8x.
- Ywhae belongs to 14-3-3 proteins, which are known to inhibit PKC. Elevated IP3 production gives rise to induced release of Ca 2+ from the en ⁇ doplasmic reticulum and further effects through Ca 2+ effector proteins.
- the genes for several calcium-modulated proteins had changed expression as follows: CaImI (calmodulini ) -4.0x, Camki (calcium/calmodulin dependent protein kinase I) -12x, S100A6 (S100 calcium binding protein A6 (calcyclin)) -5.3x, and Atp2c1 (ATPase, Ca 2+ -sequestering) -32x.
- CaImI calmodulini
- Camki calcium/calmodulin dependent protein kinase I
- S100A6 S100 calcium binding protein A6 (calcyclin)
- Atp2c1 ATPase, Ca 2+ -sequestering
- PIs play a key role in signal transduction, cytoskeleton remodeling, cell migration, and vesicular/membrane trafficking.
- Changes in the Pl-kinase/phosphatase cas ⁇ cade affect the expression of their regulators and effectors, such as small GTPases (Ras, Rho, Rab, Arf and Ran).
- Ras GTPases lead to alterations in gene transcription, Rhos regulate the actin cytoskeleton, Rab and Arf family GTPases control the formation, fusion, and movement of vesicular traffic between the differ- ent membrane compartments of the cells, Rans regulate both microtubule organi ⁇ zation and nucleocytoplasmic protein transport.
- Trim which is also a member of the Arf family and known to be an activator of PLD and active in the movement of intracellular transport vesicles, was downregulated (-9.8x).
- GabarapH (-37x)
- Gaba receptors gamma-aminobutyric acid receptors
- Picalm -5.3x
- Iqgapi (-4.6x), Cdc42 (-4x), and Rhoq (-3.2x) were also downregulated.
- Tumor suppressors including Rapib (-4x), Pfn1 (-3.5x), and Rhob (-2.6x), were affected.
- Myoib (-44x) is a calmodulin- and actin-associated myosin molecular motor also present in microvilli, which disappeared in the epithelial cells of PAP " ' " prostates.
- Tpm1 (-42x), which induces stress fibers and functions as a tumor suppressor, Enah (-28x), actin-binding proteins, Spink3 (-119x), which is essential for the main- tenance of the integrity of acinar cells, and Dnajb ⁇ (-45x), a regulator of filament organization, are all downregulated.
- Microtubules constitute an important part of the cytoskeleton and are functionally involved in mitosis, membrane traffic, and cell movement.
- Microtubule-dependent motor proteins such as Kif21a (-37x), Rp2h (-3Ox), and the cell adhesion and polarity regulators Rds (-6x), Cdc42 (-4x), and Rac1 (-3x), were downregulated as well.
- MAPK/Erk signaling pathway is imbalanced and Akt is functional
- PI(3,4,5)P 3 accounts for a number of cellular func ⁇ tions via PI3K/Akt signaling: cell growth, proliferation, resistance to apoptosis, regulation of cytoskeleton dynamics, membrane trafficking, and responses of insu ⁇ lin, and it is a substrate of PTEN. Resting mammalian cells contain significant lev- els of PI(3)P, and it is under debate whether the overall level of PI(3)P is increased upon cellular stimulation. The levels of the other 3-PIs rise, but probably never reach the levels of PI(4,5)P2 or PI(4)P. PI(3)P is associated with the endosome system and is at the lipid rafts subdomain of the plasma membrane after insulin induction. Both in yeast and in C.
- PAP ' " prostates
- exocytosis was increased.
- PAP has a putative cholesterol binding domain, but its effect on cholesterol-dependent clusters is not known.
- One mechanism underlying the detected reduced secretion of PAP " ' " epithelial cells of prostate may be cholesterol depletion.
- Inactivation of Pl- phosphatases results in disturbed vesicular/membrane trafficking.
- Synaptojanin 1 which is a presynaptic Pl-phosphatase, is a regulator of synaptic vesicle recycling, and neurons of synanpojanin 1 -deficient mice show elevated PI(4,5)P2 levels and accumulation of clathrin-coated vesicles in nerve endings.
- MTM1 myotubularin
- CMT Charcot-Marie-Tooth disease
- MTMR2 myotubularinrelated protein 2
- Pl 3-phosphatase myotubularinrelated protein 2
- This demyelinating motor and sensory neuropathy is characterized by the presence of focally folded myelin sheaths.
- CMT 2B which is a peripheral sensory axonal neuropathy causing sen ⁇ sory loss and distal muscle weakness and atrophy, is linked to chromosome 3q21 , and thereby to the missense mutation in Rab7 colocalizing with PI(3)P to late en ⁇ dosomes.
- the chromosomal location of PAP was mapped to 3q21-q23.
- Rab5 another endosomal regulator
- PAP PAP " ' " prostates. It regulates the production of PI(3)P by directly phosphorylating Pl via PI3K or by interacting with an enzymatic cascade of PI3K, PI5 and PI4- phosphatases. It can directly interact with a microtubule motor and stimulate the stable association of endosomes with microtubules by regulating endosomal dock ⁇ ing, fusion, and motility on microtubules.
- Downregulation of Rab ⁇ a has been ob ⁇ served in metastatic prostate cancer and is suggested to have a role in oncogene ⁇ sis.
- PAP is transported onto the endosomal path- way. It is secreted both in prostate and in salivary gland. In saliva, it may also have phytase activity. It has a lysosomal targeting signal and is detected in lysosomes. It also has putative caveolin and cholesterol-binding domains, and we conclude that it might be taken back into cells by the endosomal pathway, but the exact mechanism is under investigation. A remarkable amount of G-protein/small G- protein signaling genes were changed, suggesting that PAP is functional on plasma membrane and endosomal pathway.
- PAP is a novel PI3-phosphatase and an important regulator of the amount/equilibrium and local distribution of phosphatidylinositol phosphates.
- This finding constitutes the molecular basis for the disease mechanism in prostate adenocarcinoma, myopathy, and neuropathy involving disturbed G-protein signaling together with disordered vesicu ⁇ lar/membrane trafficking and cytoskeletal organization.
- mice with a modified PAP gene were generated.
- Neomycin phosphotransferase (neo) gene was inserted into exon 3 of the PAP genomic fragment ( Figure 1A) and gene tar ⁇ geting was carried out in embryonal stem (ES) cells.
- ES embryonal stem
- Homologous recombination at the PAP locus occurred in two out of 27 ES cell clones analyzed by PCR.
- Ho- mozygous PAP ⁇ 3 mice with homogenous genetic background were generated using standard methods and correct targeting was confirmed with Southern blot analyses (Figure 1B).
- PAP present in PAP r/' m ⁇ ce was catalytically inactive.
- 129SVJ/I_ambda FIXII mouse genomic DNA library (Stratagene) was screened with the cDNA encoding rPAP (Roiko et al.: Primary structure of rat secretory acid phosphatase and comparison to other acid phosphatases, Gene 1990, 89(2): 223- 9; Porvari et al., Differential androgen regulation of rat prostatic acid phosphatase transcripts, Biochem Biophys Res Commun 1995, 213(3):861-8). Genomic clone of the mPAP containing exons 3-7 was isolated. An around 7 kb BamHI fragment of this clone was used as a base of the targeting construct.
- Neo gene from pTV-0 vector was cloned into the exon 3 near the 5 ' end of the construct.
- Thymidine kinase (tk) gene was added after the long arm of mPAP sequence.
- the linearized targeting construct was electroporated into ES cells, and clones were selected ac ⁇ cording to G-418 and ganciclovir resistance. Correct targeting was screened by PCR and positive clones were further analyzed with Southern blotting.
- the micro- injection method was used to generate chimeric mice and back-crossing was car ⁇ ried out in order to obtain PAP " ' " mice with a homogeneous genomic background.
- PIP stripsTM The binding of human PAP to phospholipids was screened using PIP stripsTM (Echelon Bioscience). 100 pmole of lysophosphatidic acid, lysophosphocholine, Pl, PI(3)P, PI(4)P, PI(5)P, phosphatidyletanolamine, phosphatidylcholine, sphin- gosine-1 -phosphate, PI(3,4)P 2 , PI(3,5)P 2 , PI(4,5)P 2 , PI(3,4,5)P 3 , phosphatidic acid, and phosphatidylserine was immobilized on a nitrocellulose strip.
- the strip was incubated with 10 ⁇ g/ml or 50 ⁇ g/ml human PAP in 4% non-fat dry milk (Valio) in TBS-T overnight at +4 0 C.
- the bound PAP was detected using polyclonal PAP an ⁇ tibody produced by us (Vihko et al., 1978, Clin. Chem. 24, 1915-1919), alkaline- phosphatase conjugated secondary antibody (Sigma), and the NBT/BCIP color reaction assay (Promega).
- a malachite green assay (BIOMOL GREEN TM, BIOMOL Research Laboratories, Inc.) adapted to a 96-well format was used to measure the released free- phosphate from PI(3)P (Echelon Bioscience Inc.). Briefly, the reaction (total vol ⁇ ume of 25 ⁇ l) containing 50 mM MES buffer, pH 6.5 and an indicated amount of PI(3)P, was initiated by adding the PAP (0.25 ⁇ g per reaction) purified from hu ⁇ man spermatic fluid as previously described (specific activity of the enzyme 397 ⁇ mol min "1 mg "1 ) (Vihko et al. 1978, Clin. Chem. 24, 1915-1919).
- IVT labeling kit Affymetrix
- Biotinylated cRNA was cleaned with Ge- neChip Sample Cleanup Module (Qiagen), fragmented to 35 to 200 nt, and hybrid ⁇ ized to Affymetrix MOE430A or MOE430_2.0 arrays that contain approximately 20,000 and 40,000 mouse transcripts, respectively. After being washed, the array was stained with streptavidin-phycoerythrin (Molecular Probes). The staining sig ⁇ nal was amplified by biotinylated anti-streptavidin (Vector Laboratories) and seo ond staining with streptavidin-phycoerythrin, and then scanned on GeneChip Scanner 3000.
- the expression data were analyzed using Affymetrix GeneChip Operating System software. Signal intensities of all probe sets were scaled to the target value of 500. The results were analyzed using the Onto-express tools program (Intelligent Sys ⁇ tems and Bioinformatics Laboratory).
- the number of apoptotic cells in PAP " ' " and PAP +/+ specimens was determined from 5 ⁇ m paraffin sections of AP and DLP by Tunnel assay using ApopTag Per- oxidase in situ Apoptosis Detection Kit (Chemicon International). Five fields of the gland were photographed, each field was divided into 16 segments and the cells were counted separately. Statistical analyses were performed by Student's two- tailed f-test.
- Tissue lysates were prepared from four-to-five-months-old PAP +/+ and PAP " ' " DLP lobes using 1 mM sodium orthovanadate containing lysis buffer to prevent en ⁇ dogenous phosphatase activity. Total amount of 40 ⁇ g of protein was loaded into the wells and proteins were separated by SDS-PAGE and analyzed by Western immunoblotting. Antibodies against pPTEN and pGSK3 ⁇ were purchased from Cell Signaling Technology and used according to the manufacturer's recommen ⁇ dation.
- Tissue specimens from mouse prostate lobes were fixed in 1% glutaraldehyde, 4% formaldehyde mixture in 0.1 M phosphate buffer for transmission electron micros ⁇ copy (TEM). They were postfixed in 1% osmiumtetroxide, dehydrated in acetone and embedded in Epon Embed 812 (Electron Microscopy Sciences). Thin sections were cut with a Reichert Ultracut ultramicrotome and examined in a Philips CM 100 transmission electron microscope. Images were captured by CCD camera equipped with TCL-EM-Menu version 3 from Tietz Video and Image Processing Systems GmbH.
- Fresh prostate tissues were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 for 2 hours, immersed in 2.3 M sucrose and frozen in liquid nitrogen for immunoelectron microscopy (IEM). Thin cryosections were cut with Leica Ul- tracut UCT microtome. For the single and double immunolabeling, the sections were first incubated in 5% BSA, 0.1% gelatin in PBS. Antibodies and gold conju ⁇ gates were diluted in 0.1% BSA-C (Aurion) in PBS. All washings were performed in 0.1% BSA-C in PBS.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Neurosurgery (AREA)
- Animal Husbandry (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE602005027098T DE602005027098D1 (de) | 2004-11-11 | 2005-11-11 | Verfahren zum testen einer verbindung auf einen therapeutischen effekt |
EP05813227A EP1812586B1 (en) | 2004-11-11 | 2005-11-11 | Method for testing a compound for a therapeutic effect |
US11/667,238 US7919671B2 (en) | 2004-11-11 | 2005-11-11 | Method for testing a compound for a therapeutic effect and a diagnostic method |
AT05813227T ATE503022T1 (de) | 2004-11-11 | 2005-11-11 | Verfahren zum testen einer verbindung auf einen therapeutischen effekt |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20041453 | 2004-11-11 | ||
FI20041453A FI20041453A0 (fi) | 2004-11-11 | 2004-11-11 | Poistogeenisen eläimen malli |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006051172A1 true WO2006051172A1 (en) | 2006-05-18 |
Family
ID=33515217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FI2005/050417 WO2006051172A1 (en) | 2004-11-11 | 2005-11-11 | Method for testing a compound for a therapeutic effect and a diagnostic method |
Country Status (6)
Country | Link |
---|---|
US (1) | US7919671B2 (enCached4) |
EP (1) | EP1812586B1 (enCached4) |
AT (1) | ATE503022T1 (enCached4) |
DE (1) | DE602005027098D1 (enCached4) |
FI (1) | FI20041453A0 (enCached4) |
WO (1) | WO2006051172A1 (enCached4) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2167118A1 (en) * | 2007-06-19 | 2010-03-31 | Chempath OY | Transmembrane prostatic acid phosphatase |
US8859252B1 (en) | 2014-01-02 | 2014-10-14 | Aerial Biopharma, Llc | Prostatic acid phosphatase, compositions comprising the same, and methods for producing and/or purifying the same |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013169749A1 (en) * | 2012-05-07 | 2013-11-14 | Cold Spring Harbor Laboratory | Phosphatidylinositol monophosphate levels as disease prognosticators |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000043548A1 (en) * | 1999-01-21 | 2000-07-27 | Board Of Regents Of The University Of Nebraska | Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer |
WO2002063013A2 (en) * | 2001-02-02 | 2002-08-15 | Mount Sinai Hospital | Human acid phosphatase gene |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060088893A1 (en) * | 2003-04-29 | 2006-04-27 | Lingappa Vishwanath R | Prostate cancer therapeutics and diagnostics based on conformers of prostatic cid phosphatase |
-
2004
- 2004-11-11 FI FI20041453A patent/FI20041453A0/fi not_active Application Discontinuation
-
2005
- 2005-11-11 US US11/667,238 patent/US7919671B2/en not_active Expired - Fee Related
- 2005-11-11 WO PCT/FI2005/050417 patent/WO2006051172A1/en active Application Filing
- 2005-11-11 AT AT05813227T patent/ATE503022T1/de not_active IP Right Cessation
- 2005-11-11 EP EP05813227A patent/EP1812586B1/en not_active Not-in-force
- 2005-11-11 DE DE602005027098T patent/DE602005027098D1/de active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000043548A1 (en) * | 1999-01-21 | 2000-07-27 | Board Of Regents Of The University Of Nebraska | Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer |
WO2002063013A2 (en) * | 2001-02-02 | 2002-08-15 | Mount Sinai Hospital | Human acid phosphatase gene |
Non-Patent Citations (3)
Title |
---|
IGAWA T. ET AL: "suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic axid phosphatase", THE PROSTATE, vol. 55, 18 April 2003 (2003-04-18), pages 247 - 258, XP008118651 * |
VIHKO P.T. ET AL: "Prostatic acid phosphatase (PAP) is (PI(3)P-phosohatase and its inactivation leads to change of cell polarity and invasive prostate cancer", PROCEEDINGS OFTHE AACR, 96TH ANNUAL MEETING, no. ABSTRACT 5239, 16 April 2005 (2005-04-16) - 20 April 2005 (2005-04-20), ANAHEIM, CA, USA, XP008118725 * |
WANG S. ET AL: "Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metstatic prostate cancer", CANCER CELL, vol. 4, September 2003 (2003-09-01), pages 209 - 221, XP008118654 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2167118A1 (en) * | 2007-06-19 | 2010-03-31 | Chempath OY | Transmembrane prostatic acid phosphatase |
EP2167118A4 (en) * | 2007-06-19 | 2010-12-08 | Chempath Oy | TRANSMEMBRANE PROSTATIC ACID PHOSPHATASE |
US8859252B1 (en) | 2014-01-02 | 2014-10-14 | Aerial Biopharma, Llc | Prostatic acid phosphatase, compositions comprising the same, and methods for producing and/or purifying the same |
Also Published As
Publication number | Publication date |
---|---|
EP1812586A1 (en) | 2007-08-01 |
EP1812586B1 (en) | 2011-03-23 |
EP1812586A4 (en) | 2009-06-03 |
US7919671B2 (en) | 2011-04-05 |
US20070292350A1 (en) | 2007-12-20 |
DE602005027098D1 (de) | 2011-05-05 |
ATE503022T1 (de) | 2011-04-15 |
FI20041453A0 (fi) | 2004-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cremona et al. | Essential role of phosphoinositide metabolism in synaptic vesicle recycling | |
Ooms et al. | The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease | |
Chien | Genes and physiology: molecular physiology in genetically engineered animals. | |
Howell et al. | Dab1 tyrosine phosphorylation sites relay positional signals during mouse brain development | |
Cao et al. | IKKα provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development | |
Wang et al. | Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer | |
Sicinski et al. | Cyclin D1 provides a link between development and oncogenesis in the retina and breast | |
Mizugishi et al. | Essential role for sphingosine kinases in neural and vascular development | |
Kubota et al. | Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. | |
Neesen et al. | Disruption of an inner arm dynein heavy chain gene results in asthenozoospermia and reduced ciliary beat frequency | |
Wani et al. | Lung Kruppel-like factor, a zinc finger transcription factor, is essential for normal lung development | |
Oldham et al. | The Drosophila insulin/IGF receptor controls growth and size by modulating PtdIns P 3 levels | |
Dupont et al. | PTEN overexpression suppresses proliferation and differentiation and enhances apoptosis of the mouse mammary epithelium | |
Nakayama et al. | Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors | |
Santos et al. | Isoprenoids control germ cell migration downstream of HMGCoA reductase | |
Cha et al. | PICOT is a critical regulator of cardiac hypertrophy and cardiomyocyte contractility | |
Zumbansen et al. | Neutral sphingomyelinase 1 deficiency in the mouse causes no lipid storage disease | |
Fujikura et al. | Kif14 mutation causes severe brain malformation and hypomyelination | |
Tinkum et al. | Forkhead box O1 (FOXO1) protein, but not p53, contributes to robust induction of p21 expression in fasted mice | |
Willis et al. | Cell-type specific expression of a dominant negative PKA mutation in mice | |
Lin et al. | Reductions in linker histone levels are tolerated in developing spermatocytes but cause changes in specific gene expression | |
WO2018175581A1 (en) | A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 MOUSE Trem2.p.R47H AND METHODS OF USE THEREOF | |
Stumpf et al. | Differential requirement for pten lipid and protein phosphatase activity during zebrafish embryonic development | |
EP1812586B1 (en) | Method for testing a compound for a therapeutic effect | |
Dyson et al. | Growth arrest of PPP2R5C and PPP2R5D double knockout mice indicates a genetic interaction and conserved function for these PP2A B subunits |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005813227 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11667238 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005813227 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11667238 Country of ref document: US |